Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $87.05M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.12pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 34.0¢ | Day High | 35.0¢ | Day Low | 33.5¢ | |||
| Daily Volume | 169602 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 33.5¢ | 86898 | 0 | 35.0¢ | 2857 | |
Directors & Senior Management
| Mr. Andrew Robert Hinkly | Non-Executive Director |
| Ms. Belinda Wilson | Chief People Officer |
| Ms. Danielle Marguerite Lee | Independent Non-Executive Director |
| Mr. David De Haas | Member of Advisory Committee |
| Mr. Glenn Corrie | MD, CEO & Executive Director |
| Ms. Joan Dabon | Company Secretary |
| Dr. John Andrew Hamilton | Independent Non-Executive Director |
| Mr. Kevin Peakman | Member of Advisory Committee |
| Mr. Luc Kox | Chief Commercial Officer |
| Mr. Neil Brodie | Chief Financial Officer |
| Mr. Tim Forbes | Chief Technical Officer |
| Mr. Timothy Goldsmith | Independent Non-Executive Chairman |
| Mr. Tom Coolican | Chief Operations Officer |
Data source: ADVFN
